EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY-NC-ND 4.0

Syndrome of Inappropriate Antidiuresis: From Pathophysiology to Management

Annabelle M Warren iD, Mathis Grossmann, Mirjam Christ-Crain, Nicholas Russell

Endocrine Reviews · 15.09.2023 · 44 (5) · 819-861

DOI: 10.1210/endrev/bnad010 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Endocrine Reviews, online erschienen am 28.03.2023. Verfasst von Annabelle M Warren und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, University of Melbourne, Victoria 3010, Australia. Hauptthemen laut MEDLINE: Hyponatremia, Inappropriate ADH Syndrome, Neoplasms. Die Arbeit wurde bisher 151-mal zitiert (Crossref) und nennt 344 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: National Health and Medical Research Council of Australia.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Hyponatremia is the most common electrolyte disorder, affecting more than 15% of patients in the hospital. Syndrome of inappropriate antidiuresis (SIAD) is the most frequent cause of hypotonic hyponatremia, mediated by nonosmotic release of arginine vasopressin (AVP, previously known as antidiuretic hormone), which acts on the renal V2 receptors to promote water retention. There are a variety of underlying causes of SIAD, including malignancy, pulmonary pathology, and central nervous system pathology. In clinical practice, the etiology of hyponatremia is frequently multifactorial and the management approach may need to evolve during treatment of a single episode. It is therefore important to regularly reassess clinical status and biochemistry, while remaining alert to potential underlying etiological factors that may become more apparent during the course of treatment. In the absence of severe symptoms requiring urgent intervention, fluid restriction (FR) is widely endorsed as the first-line treatment for SIAD in current guidelines, but there is considerable controversy regarding second-line therapy in instances where FR is unsuccessful, which occurs in around half of cases. We review the epidemiology, pathophysiology, and differential diagnosis of SIAD, and summarize recent evidence for therapeutic options beyond FR, with a focus on tolvaptan, urea, and sodium-glucose cotransporter 2 inhibitors.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

HyponatremiaInappropriate ADH SyndromeNeoplasmsHumansWater-Electrolyte Balance

Stichwörter der Autor:innen

empagliflozinfluid restrictionhyponatremiasodium-glucose cotransporter 2 inhibitors (SGLT2i)syndrome of inappropriate antidiuresis (SIAD)tolvaptanurea

Autor:innen und Institutionen

  • Department of Medicine, University of Melbourne, Victoria 3010, Australia.
  • Department of Endocrinology, The Austin Hospital, Victoria 3084, Australia.
  • Department of Endocrinology, Diabetology and Metabolism, University Hospital Basel, Basel 4031, Switzerland.
  • Department of Clinical Research, University of Basel and University Hospital Basel, Basel 4031, Switzerland.

ORCID-Profile: Annabelle M Warren

Förderung

  • National Health and Medical Research Council of Australia

Zitieren

APA

Warren, A. M., Grossmann, M., Christ-Crain, M., & Russell, N. (2023). Syndrome of Inappropriate Antidiuresis: From Pathophysiology to Management. Endocrine Reviews, 44(5), 819-861. https://doi.org/10.1210/endrev/bnad010

Vancouver

Warren AM, Grossmann M, Christ-Crain M, Russell N. Syndrome of Inappropriate Antidiuresis: From Pathophysiology to Management. Endocrine Reviews. 2023;44(5):819-861. doi:10.1210/endrev/bnad010

BibTeX
@article{Warren2023,
  author = {Warren, Annabelle M and Grossmann, Mathis and Christ-Crain, Mirjam and Russell, Nicholas},
  title = {Syndrome of Inappropriate Antidiuresis: From Pathophysiology to Management},
  journal = {Endocrine Reviews},
  year = {2023},
  volume = {44},
  number = {5},
  pages = {819--861},
  doi = {10.1210/endrev/bnad010}
}
Kostenlos starten →